Sumitomo Dainippon Pharma invest $3 bn in Swiss Roivant

Sumitomo Dainippon Pharma to invest $3 bn in Swiss Roivant

11:04 AM, 6th September 2019
Sumitomo Dainippon Pharma logo

TOKYO, JAPAN: Sumitomo Dainippon Pharma Co will pay $3 billion for a 10% stake in Swiss drugmaker Roivant Sciences Ltd and interests in five of its biopharmaceutical businesses, the two companies said.

The deal, which will open up new drug lines for Sumitomo Dainippon, will also give it the option to acquire interests in an additional six businesses, as well as access to Roivant's technology platforms, they said.

The deal comes as Sumitomo Dainippon's schizophrenia treatment Latuda is due to lose its U.S. market exclusivity in 2023. The Japanese company will take ownership of Roivant units that develop treatments for prostate cancer, urinary diseases, pediatric illnesses and respiratory diseases, they said.

A fifth business unit will also be transferred before the deal's conclusion.

The 11 businesses include more than 25 clinical programs with multiple product launches expected between 2020 and 2022, the two companies said.

Source: Reuters

0 Comments

Login

Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News


Hempel launches new coating system - Hempaguard MaX

LYNGBY, DENMARK: Hempel has launched an innovative new fouling defence system – Hempaguard MaX. This unique three-coat system provides vessels w ...

Read more
LyondellBasell, Bora sign MoU for China expansion

ROTTERDAM, NETHERLANDS/HONG KONG, CHINA: LyondellBasell has signed a memorandum of understanding (MoU) to expand in China through a Joint Venture (JV) ...

Read more
Mexichem changes name to Orbia

BOSTON, US: Mexichem S. A.B. de C.V, a global leader in specialty products and innovative solutions, has reached next milestone by unveiling its new c ...

Read more
Total appoints new chief financial officer

PARIS, FRANCE: Total SA has appointed two new members to its executive committee. Jean-Pierre Sbraire is appointed as new chief financial officer foll ...

Read more
Lindsay Goldberg to buy pharma packaging maker Bilcare Research: Sources

FRANKFURT, GERMANY: Private equity investor Lindsay Goldberg has agreed to buy Bilcare Research, in a deal valuing the Swiss pharma packaging group at ...

Read more
Total makes final investment decision on Arctic LNG 2 along with partners

PARIS, FRANCE: Total SA, Novatek and other shareholders have approved the final investment decision (FID) for Arctic LNG 2. Arctic LNG 2 is a major l ...

Read more
www.worldofchemicals.com uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X